Efficacy of sacituzumab govitecan in triple-negative breast cancer with hepatic visceral crisis: a case report

TL;DR

This case report shows that sacituzumab govitecan can effectively treat triple-negative breast cancer with severe liver metastasis.

Contribution

The novelty lies in demonstrating SG's efficacy in a rare and severe clinical scenario of hepatic visceral crisis in TNBC.

Findings

A TNBC patient with diffuse liver metastasis achieved significant remission after two cycles of SG treatment.

The patient had a progression-free survival of 16.3 months following SG therapy.

Abstract

Triple-negative breast cancer (TNBC) is recognized as the most aggressive molecular subtype of breast cancer (BC). The liver is a common site of distant metastasis in BC, and hepatic involvement is associated with accelerated therapeutic resistance and increased mortality risk. Although sacituzumab govitecan (SG) has shown favorable clinical efficacy in the treatment of BC with liver metastasis in the ASCENT randomized controlled trial and real-world studies, its application value in hepatic visceral crisis (HVC) remains inadequately investigated. Herein, we report the clinical course and outcomes of a TNBC patient with diffuse liver metastasis. Following two cycles of SG treatment, the patient achieved significant remission of liver lesions, with a progression-free survival (PFS) of 16.3 months. This case report highlights the necessity of conducting further in-depth studies to explore the application of SG in BC patients with visceral crisis (VC).

Figures